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Interactions between tumorigenic cells and their
surrounding microenvironment are critical for tumor
progression yet remain incompletely understood.
Germline mutations in the NF1 tumor suppressor
gene cause neurofibromatosis type 1 (NF1), a com-
mon genetic disorder characterized by complex tu-
mors called neurofibromas. Genetic studies indicate
that biallelic loss of Nf1 is required in the tumorigenic
cell of origin in the embryonic Schwann cell lineage.
However, in the physiologic state, Schwann cell loss
of heterozygosity is not sufficient for neurofibroma
formation and Nf1 haploinsufficiency in at least
one additional nonneoplastic lineage is required
for tumor progression. Here, we establish that Nf1
heterozygosity of bone marrow-derived cells in the
tumor microenvironment is sufficient to allow neuro-
fibroma progression in the context of Schwann cell
Nf1 deficiency. Further, genetic or pharmacologic
attenuation of c-kit signaling in Nf1+/ hematopoietic
cells diminishes neurofibroma initiation and progres-
sion. Finally, these studies implicate mast cells as
critical mediators of tumor initiation.
INTRODUCTION
Mutations in the NF1 tumor suppressor gene cause neurofibro-
matosis type 1 (NF1), a common, pandemic human genetic
disorder that affects approximately 250,000 patients in the US,Europe, and Japan alone. TheNF1 gene encodes neurofibromin,
a 320 kilodalton protein that functions at least in part as a
GTPase-activating protein (GAP) for p21ras (Viskochil et al.,
1990; Wallace et al., 1990). The NF1 cDNA is highly conserved
among vertebrate species, with considerable homology extend-
ing to yeast and Drosophila (Bollag and McCormick, 1991;
Martin et al., 1990).
Individuals with NF1 have a wide range of malignant and non-
malignant manifestations, including plexiform neurofibromas
that collectively affect 25%–40%of NF1 patients and are amajor
source of lifelong morbidity and mortality. Neurofibromas form
in association with peripheral nerves and are composed of
Schwann cells, endothelial cells, fibroblasts, degranulating in-
flammatory mast cells, and pericytes/vascular smooth muscle
cells (VSMCs) and contain large collagen deposits. Using an
Nf1 conditional knockout mouse model, we have confirmed ret-
rospective studies from human tumors and demonstrated that
Nf1 loss of heterozygosity (LOH) in the Schwann cell lineage is
necessary but not sufficient to elicit neurofibromas (Zhu et al.,
2002). In addition, we have reported that tumor progression
requires complex interactions between Schwann cells and Nf1
heterozygous (Nf1+/)cell lineages in the tumormicroenvironment
(Zhu et al., 2002). Thus, in anNf1wild-type (WT) background,Nf1
deficiency (Nf1/) in Schwann cells is necessary but not suffi-
cient to cause tumor formation. A hallmark of the tumor forming
heterozygous mice is the appearance of mast cells in peripheral
nerves well in advance of tumor development (Zhu et al., 2002).
In addition, in vitro experiments mixing conditioned media from
Schwann cells and mast cells have demonstrated a hypersensi-
tivity of Nf1 heterozygous mast cells to conditioned media from
Nf1-deficient Schwann cells (Yang et al., 2003). Taken together
these preceding studies have provided the basis for a modelCell 135, 437–448, October 31, 2008 ª2008 Elsevier Inc. 437
that Nf1 heterozygous mast cell infiltration of preneoplastic
peripheral nerves and association with Nf1-deficient Schwann
cells is critical for tumor development.
In the present study, we validate the role of NF1 heterozygous
bone marrow-derived cells in plexiform neurofibroma formation.
Further, on the basis that c-kit receptor activation controls the
release of mast cells from the bone marrow, we use both phar-
macologic and genetic inhibition of this receptor to prevent or
delay plexiform neurofibroma formation in Nf1 mice. These
results establish that Nf1 haploinsufficiency of bone marrow-
derived cells and in particular those dependent on activation of
the c-kit receptor is required in the tumor microenvironment to
allow neurofibroma progression. The data implicate mast cells
as active participants in tumor formation and identify therapeutic
targets for human phase 1-2 clinical trials.
RESULTS
Transplantation of Nf1+/ Bone Marrow into Recipients
with Biallelic Loss of Nf1 in Schwann Cells Promotes
Increased Morbidity and Mortality
To test the hypothesis that heterozygosity ofNf1 in hematopoietic
cells within the tumormicroenvironment is responsible for the ge-
netic haploinsufficiency required for neurofibroma formation, we
transferredNf1 heterozygous bonemarrow into lethally irradiated
mice harboring two Krox20-Cre transgene ablated Nf1 alleles in
Figure 1. Strategy to Examine the Role of the Hematopoietic
Microenvironment in Neurofibroma Formation
(A) Experimental design; schematic showing the genotypes of recipient mice,
the genotypes of bone marrow cells following ionizing radiation of recipients,
and measurements obtained following transplantation.
(B) Identification of donor bone marrow using fluorescence cytometry. Repre-
sentative histograms of donor bone marrow cells isolated from previously
irradiated Krox20;Nf1flox/flox recipients. The genotypes of transplanted cells
are indicated. Dotted lines indicate the EGFP fluorescence intensity of bone
marrow that lacks the EGFP transgene.438 Cell 135, 437–448, October 31, 2008 ª2008 Elsevier Inc.approximately 10% of Schwann cells (Krox20;Nf1flox/flox).
Krox20;Nf1flox/flox mice are functionally WT in all non Schwann
cell lineages and no neurofibromas are observed. As a comple-
mentary experiment, WT bone marrow cells were transplanted
into lethally irradiated mice containing a germline knockout allele
of Nf1 and a floxed allele susceptible to recombination in the
Schwann cell lineage as above (Krox20;Nf1flox/).Krox20;Nf1flox/
mice uniformly develop plexiform neurofibromas as previously
described (Zhu et al., 2002). To identify donor cells and their prog-
eny within the recipients, the Nf1+/ and WT donors were inter-
crossed with a transgenic mouse that expresses EGFP in all
bone marrow cells (Okabe et al., 1997). The intercrossed Nf1+/
or WT bone marrow that also expresses EGFP was transplanted
into recipients following ionizing radiation, and the development
of plexiform neurofibromas and mortality associated with these
tumors was monitored until one year of age. A schematic of
the experimental design is outlined in Figure 1A. Representative
histograms of bone marrow cells in stably reconstituted mice
showing EGFP fluorescence is shown in Figure 1B.
Six months after transplantation, the functional germline WT
(Krox20;Nf1flox/flox) recipients engrafted with heterozygousNf1+/
bone marrow began to exhibit motor paralysis, weight loss and
only 15%ofmice survived the entire experimental period (Figures
2A and 2B). Thismortality rate largelymirrored that previously ob-
served in the germline heterozygous Krox20;Nf1flox/ mice
(Figure 2A). In contrast, approximately 90% of Krox20;Nf1flox/flox
mice reconstituted with WT bone marrow were alive and ex-
hibited no clinical features of plexiform neurofibroma formation
(Figure 2A). Critical validation of these data was provided by
the converse experiment in which transplantation of WT bone
marrow cells into germline Nf1 heterozygous, Krox20;Nf1flox/,
mice restored survival comparable to nontumorigenic
Krox20;Nf1flox/flox mice that contain intact bone marrow (Fig-
ure 2A). Necropsy of the brains and spinal cords of the morbid
mice revealed that 21 of 22Nf1+/ bone marrow transplant recip-
ients had an increased thickness of the entire spinal cord as com-
pared to the spinal cords of nonsymptomatic mice transplanted
with WT bone marrow (Figure 2C). This abnormal morphology
resembles the tumorigenic Krox20;Nf1flox/ mice. In addition,
we observed multiple, discrete tumors arising from the dorsal
root ganglia of Krox20;Nf1flox/flox mice transplanted with Nf1+/
bone marrow and these tumors were particularly prevalent in
the sciatic nerves (Figure 2C, panels 3 and 4). Volumetric analysis
of the tumors revealed a 3- to 6-fold increase in volume
compared to unaffected dorsal root ganglia in mice that did not
develop tumors. The large size and anatomic location of the tu-
mors infiltrating the sciatic nerve and lumbosacral plexus likely
account for the observed behavioral abnormalities (Figure 2B
and Table S1 available with this article online). In sum, these
data indicate that presence of Nf1 heterozygous bone marrow
in the context of Schwann cell loss of heterozygosity is sufficient
to recapitulate the morbidity and peripheral nerve hyperplasia
originally observed in Krox20;Nf1flox/ tumorigenic mice.
Nf1+/ Bone Marrow Recipients Develop Plexiform
Neurofibromas
Pathologic analysis confirmed the presence of plexiform neuro-
fibromas in 21 of 22 Nf1 heterozygous bone marrow recipients
(Figure 3A). The dorsal root ganglia from Krox20;Nf1flox/flox mice
transplanted with Nf1+/ bone marrow exhibit classic histologi-
cal features of human plexiform neurofibromas including disrup-
tion of normal architecture; wavy Schwann cells and infiltrating
cells with hyperchromatic nuclei (Figure 3A, panels 7 and 8);
excess collagen deposition (Figure 3B, panels 2 and 3);
angiogenesis (Figure 3C, yellow arrowheads); classic ultrastruc-
tural abnormalities (Figure S1) and Schwann cell-specific
markers (Figure S2). In contrast, the nerves from either
Krox20;Nf1flox/flox or Krox20;Nf1flox/ mice transplanted with
Figure 2. Nf1+/ Bone Marrow Is Necessary for Plexiform Neurofi-
broma Formation in Krox20;Nf1flox/flox and Krox20;Nf1flox/ Mice
(A) Previously irradiated Krox20;Nf1flox/flox and Krox20;Nf1flox/ mice trans-
planted with Nf1+/ or WT bone marrow were followed until 1 year of age. A
Kaplan-Meier plot of percent survival (y axis) as a function of time (x axis) is
shown. The genotypes are indicated. Comparisons of Krox20;Nf1flox/flox+
Nf1+/ BM (dashed line) versus Krox20;Nf1flox/flox+WT BM (open squares) (p <
0.002); Krox20;Nf1flox/flox+ Nf1+/ BM (dashed line) versus Krox20;Nf1flox/
(open circles) (no significant difference). Krox20;Nf1flox/ (open circles) versus
Krox20;Nf1flox/ + WT bone marrow (closed squares) (p < 0.0002).
(B) Photographs of Krox20;Nf1flox/flox mice transplanted with WT BM (1) or
Nf1+/ BM (2 and 3). Arrowheads identify limbs with motor paralysis.
(C) Dissections of dorsal root ganglia and peripheral nerves ofKrox20;Nf1flox/flox
mice transplanted withWT orNf1+/ bonemarrow. Arrowheads identify tumors
in dorsal root ganglia and proximal peripheral nerves.WTmarrow exhibited normal appearing evenly distributed nuclei
throughout sections of the dorsal root ganglia and proximal
peripheral nerves (Figure 3A, panels 1, 4–6, 9, and 10). These
mice showed no evidence of collagen deposition (Figure 3B,
panels1, 4, and 5), neovascularization, and retained normal ultra-
structural morphology (Figure S1).
Neurofibromas Are Infiltrated with Donor Mast Cells
As described above, neurofibromas are complex tumors com-
prising multiple cell types in which LOH is uniquely present in
the Schwann cell lineage (Zhu et al., 2002). Mast cell infiltration
is characteristic of human and murine plexiform neurofibromas
(Hirota et al., 1993; Zhu et al., 2002). In our mousemodel, we ob-
serve peripheral nerve infiltration by mast cells preceding tumor
appearance. Accordingly, the Nf1+/ bone marrow of reconsti-
tuted Krox20;Nf1flox/flox mice also exhibited extensive mast cell
infiltration as evidenced by mast cell-specific stains (Figures
3C, panels 2 and 3, 3D, and S3). To further discern the identity
of bone marrow-derived lineages in the tumor, fluorescence cy-
tometry was utilized to identify hematopoietic cells (CD45.2+) in
the neurofibromas of Krox20;Nf1flox/flox mice transplanted with
Nf1+/ bone marrow (Figure 3E). In 12 tumors examined, a range
of 3%–7% of the cells were hematopoietic cells (CD45.2+;
EGFP+). From this population, the majority of cells were identi-
fied as mast cells (CD117+; Fc3RI+;EGFP+, Figure 3E, panel
3). A small population of macrophages (Figure 3D, panel 4) and
rare B lymphocyte and T-lymphocyte populations were also
observed (Figure 3E, panels 4 and 5). Consistent with the
histological sections, there were no comparable populations of
hematopoietic cells observed in dorsal root ganglia from
Krox20;Nf1flox/flox mice transplanted with WT bone marrow
(data not shown). Subsequent genotyping confirmed that hema-
topoietic but not endothelial or fibroblast populations harbored
theNf1 null allele (Figure 3F). These data confirm the appearance
of bona fide plexiform neurofibromas in the reconstituted
Krox20;Nf1flox/flox mice including homing of the transplanted
heterozygous mast cells to the sites of Nf1-deficient Schwann
cells. Collectively, the bone marrow transplantation experiments
into Krox20;Nf1flox/flox mice demonstrate that in the context
of disruption of Nf1 in the embryonic Schwann cell lineage,
Nf1+/ bone marrow is sufficient for tumor progression. Further-
more, the converse experiment of transplanting WT bone
marrow into tumor prone Krox20;Nf1flox/ mice demonstrates
that in this mouse model, Nf1+/ bone marrow is required for
tumor progression.
Nf1+/ Bone Marrow-Mediated Tumor Formation
Requires c-kit
The fact that the only Nf1+/ cells detected in the reconstituted
plexiform neurofibromas were bone marrow-derived was con-
sistent with our previous in vitro and in vivo observations
implicating a mast cell haploinsufficiency requirement in tumor
formation (Ingram et al., 2000; Yang et al., 2003; Zhu et al., 2002).
The c-kit receptor tyrosine kinase (RTK) controls many aspects
of mast cell development and function (Galli et al., 1993). We
have reported that c-kit activity governs migration, proliferation,
and survival of Nf1+/ bone marrow-derived mast cells (IngramCell 135, 437–448, October 31, 2008 ª2008 Elsevier Inc. 439
Figure 3. Tumors Isolated from Krox20;Nf1flox/flox Mice Transplanted with Nf1+/ Bone Marrow Have Histologic Features of Plexiform
Neurofibromas
(A) Hematoxylin and eosin (H&E) sections of dorsal root ganglia and proximal peripheral nerves. Panels 1 and 6 are sections from a Krox20;Nf1flox/flox mouse
transplanted with WT BM. Panels 2, 3, 7, and 8 are from Krox20;Nf1flox/flox mice transplanted with Nf1+/ BM. Panels 4, 5, 9, and 10 are from Krox20;Nf1flox/
mice transplanted with WT BM. Photos in upper panels were taken with a light microscope under 1003, whereas the lower panels were taken under 4003.
(B) 2003 magnification of sections stained with Masson’s trichrome. Genotypes of donor bone marrow and recipient mice are indicated.440 Cell 135, 437–448, October 31, 2008 ª2008 Elsevier Inc.
et al., 2000, 2001; Yang et al., 2003). We therefore next tested
whether genetic disruption of c-kit activity inNf1+/ bonemarrow
cells transplanted intoKrox20;Nf1flox/floxmice would affect tumor
progression.
Nf1+/ mice were independently intercrossed with two hypo-
morphic strains of mice deficient in mast cell mobilization by
virtue of point mutations in the c-kit receptor that reduce kinase
activity 85% (W41/W41) or 95% (Wv/Wv), respectively. The bone
marrow from either Nf1+/;Wv/Wv or Nf1+/;W41/W41 doubly
mutant mice was transplanted into five and ten recipient
Krox20;Nf1flox/floxmice respectively that had been previously irra-
diated with a dosage of ionizing radiation that induces bonemar-
row failure and lethality in the absence of a donor graft (Haneline
et al., 1999). Morbidity of mice engrafted with Nf1+/;W mutant
marrow was significantly reduced as compared to Nf1flox/flox
mice transplanted with Nf1+/ bone marrow (Figure 4A). Accord-
ingly, in contrast to recipients of Nf1+/ bone marrow, the dorsal
root ganglia and proximal peripheral nerves from the
Krox20;Nf1flox/flox mice transplanted with Nf1+/;W mutant
marrow do not exhibit gross evidence of tumors (Figures 4A–
4C). Furthermore, they do not exhibit histological features of neu-
rofibromas (Figure 4D) nor evidence of invading hematopoietic
cells as measured by fluorescence cytometry (data not shown).
Despite the fact that recipient mice are lethally irradiated prior
to bone marrow transplant, it is well known that W mutant bone
marrow can be competitively overcome by wild-type bone mar-
row in vivo. Because of the complexity of intercrossing multiple
alleles and infertility of the Wv/Wv mice, it was not possible to in-
tercross the EGFP allele onto the intercrossed Nf1+/;W mutant
line. Therefore to rule out the possibility of any residual wild-
type (Nf1flox/flox) recipient bone marrow overcoming the donor
Nf1+/;W bone marrow, we verified the predominant presence of
the donor heterozygous genotype in bone marrow derivatives of
engrafted animals (Clapp et al., 1995; Jordan et al., 1990). South-
ern blot analysis of bone marrow from five randomly selected
Nf1flox/flox;Krox20-cre recipients demonstrated predominant
(>85%–100%) presence of the Nf1+/ genotype indicating
effective donor engraftment of heterozygous bone marrow (Fig-
ure S4A). In addition, DNA from forty individual granulocyte mac-
rophage and mast cell progenitors from each recipient, which
grow as individual colonies in semisolid medium, was examined
for detection of the Nf1 knockout, WT and Cre/lox alleles
(Figure S4B). Approximately 95% of all progenitors examined
(193/200) contained the Nf1 knockout allele but not the Nf1flox/flox
allele. Collectively, these molecular data demonstrate the
effective engraftment of donor marrow and further refine the
identity of the active component of the Nf1+/ marrow to a c-kit
dependent cell type.Pharmacologic Inhibition of c-kit Reduces Tumor Size
and Metabolic Activity
The availability of pharmacologic agents that can inhibit c-kit
receptor activity permitted us to next examine whether such
agents could affect neurofibroma formation or persistence. Ima-
tinib mesylate is a potent inhibitor of the c-kit, PDGFR, and c-abl
tyrosine kinases. To assess the activity of imatinib mesylate and
other potential pharmacologic agents on tumor burden we
validated a noninvasive fluoridinated deoxyglucose positron
emission tomography (FDG-PET) imaging protocol permitting
identification and longitudinal observation of plexiform neurofi-
bromas in Krox20;Nf1flox/ mice (see Experimental Procedures
and Figures S5A–S5C).
We next selected cohorts of 8- to 9-month-oldKrox20;Nf1flox/
mice with confirmed PET positive uptake in the region of the
sciatic nerve for oral treatment with either 200 mg/kg/day of im-
atinib mesylate or a placebo control (PBS). FDG-PET imaging
studies followed to evaluate the evolution of the tumors. Repre-
sentative FDG-PET axial slices of affected nerves from three
mice imaged before and after treatment with imatinib mesylate
or PBS for 3 weeks are shown in Figure 5A. As predicted,
increased FDG uptake was seen in Krox20;Nf1flox/ animals lat-
eral to the spine prior to treatment with either imatinib mesylate
or PBS (Figure 5A, panels 1, 3, and 5). Strikingly, FDG uptake
was qualitatively reduced in the Krox20;Nf1flox/ mice treated
with imatinib mesylate (Figure 5A, panels 2–4) compared to
the PBS controls (Figure 5A, panel 6). To carefully measure
the FDG-PET intensity in all treated animals, a standardized
region of interest (ROI) was utilized in each animal to extract
quantitative FDG uptake values (mCi/ml tissue). Three
dimensional ROIs in the shape of cylinders were utilized to en-
capsulate the areas lateral to the spinal column with the ROI
cylinders and specific vertebrae landmarks (lumbar 1-sacral
1) were used in all cases to assure consistency. Representative
results from one experimental animal, before and after treat-
ment, are shown in panels 7 and 8 (Figure 5A). A summary of
these results for the sciatic nerve region ROIs of one cohort
of 12 experimental mice are plotted in Figure 5B. Overall, the
mice treated with imatinib mesylate had a mean 50% reduction
in FDG-PET uptake after treatment (p < 0.035). In contrast, the
metabolic activity of the tumors in the cohort treated with PBS
had a modest but not significant increase in the FDG uptake
ratio comparable to the progressive uptake in FDG observed
as a function of time in emerging plexiform neurofibromas in
Krox20;Nf1flox/ mice.
To determine whether a change in metabolic activity (FDG
uptake) directly correlated with histological changes in the
tumors, the imaged cohorts were sacrificed, the spinal cords(C) 2003 magnification of sections stained with alcian blue. Red arrowheads identify mast cells. Yellow arrowheads identify blood vessels. High power
magnification (10003) insets of mast cells are indicated.
(D) Summary data indicating the number of mast cells scored within tumors or dorsal root ganglia (DRG) of Krox20;Nf1flox/flox and Krox20;Nf1flox/ recipients. Data
represent the mean ± standard error of the mean (SEM) of five tumors or DRG per group. The genotypes of the donors and recipient mice are indicated. An
asterisk indicates p < 0.001 significance of mast cells identified in recipients who received Nf1+/ versus WT bone marrow.
(E) Phenotypic evaluation of bone marrow-derived lineages using fluorescence cytometry. Bone marrow (panel 1) and tumor cells (panel 2) were isolated and
sorted for EGFP+; CD45.2 positive populations. Tumor associated CD45.2 cells were then further separated to identify mast cell (panel 3), macrophage (panel
4), B-lymphocyte (panel 4), and T-lymphocyte populations (panel 5). The proportion of each hematopoietic cell population within the tumor is indicated.
(F) Genotyping of lineages isolated by FACS from tumors of Krox20;Nf1flox/flox mice transplanted with Nf1+/ BM. Arrows identify the amplified DNA products of
the indicated alleles from the respective phenotypic lineages.Cell 135, 437–448, October 31, 2008 ª2008 Elsevier Inc. 441
were examined, and sections were prepared for histologic
evaluation. At postmortem, we also compared the volumes of
all dorsal root ganglia from an age equivalent cohort of
Krox20;Nf1flox/flox mice. Consistent with the FDG-PET imaging
Figure 4. Genetic Disruption of c-kit in
Adoptively Transferred Nf1+/BoneMarrow
Prevents the Genesis of Plexiform Neurofi-
bromas in Recipient Krox20;Nf1flox/flox Mice
(A) Krox20;Nf1flox/flox mice were transplanted with
Nf1+/ or Nf1+/;W mutant BM. A Kaplan-Meier
plot of percent survival (y axis) as a function of
time (x axis) is shown. The genotypes are indi-
cated. An asterisk indicates p < 0.002 comparing
survival of the two experimental groups.
(B) Photographs of the spinal cord and dorsal
roots of Krox20;Nf1flox/flox mice transplanted with
WT BM (panel 1) or Nf1+/ BM (panel 2). Arrows
identify tumors in proximal nerves.
(C) Mean size of dorsal root ganglia (DRG) from
the sciatic nerves of recipients transplanted with
Nf1+/ or Nf1+/;W/W bone marrow. Each dot
represents the size of an individual DRG. The line
indicates the mean size of all DRG. An asterisk in-
dicates p < 0.01 comparing size of DRG between
two groups.
(D) Representative histologic sections of dorsal
root ganglia and proximal spinal nerves of
Krox20;Nf1flox/flox mice transplanted with Nf1+/
or Nf1+/;W/W mutant marrow. Panels 1–3 are
sections stained with H&E; panels 4–6 are stained
with alcian blue. Arrowheads indicate mast
cells. The genotypes of donor bone marrow are
indicated.
studies, there was a clear decrease in
dorsal root ganglia volume in the imatinib
mesylate treated group as compared to
the PBS treated group (Figure 5C).
Histological evaluation of the dorsal
root ganglia and proximal surrounding
nerves in mice treated with either imatinib
mesylate or PBS was also conducted.
Nerves harvested from placebo treated
mice showed a distinct disruption of the
normal nerve architecture and an in-
crease in cellularity compared to imatinib
mesylate treated mice. This is illustrated
in tissue sections showing the distal
dorsal root and proximal nerve segments
(Figure 5D, panels1–6 compared to
7–12). Further, there is a marked reduc-
tion in the number of mast cells in nerves
dissected frommice treated with imatinib
mesylate compared to PBS treated
controls (Figure 5D, panels 3 and 4 versus
9 and 10, Figure 5E). This reduction in
tumor size is also associated with
both an increase in apoptotic cells within
the tumor (Figures 5F and S6) and a
decrease in proliferation (Figure 5G). Collectively, the PET,
gross anatomic and histological data identify the potential for
imatinib mesylate to reduce tumor volume in Krox20;Nf1flox/
mice.
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Imatinib Mesylate Treatment Reduces Plexiform
Neurofibroma Size and Associated Symptoms
Plexiform neurofibromas primarily present in infants and young
children with NF1 and are frequently characterized by rapid
growth and invasion into adjacent organs often resulting in im-
pairment of normal organ function. These tumors can be life
threatening and present major clinical challenges as surgical
treatment has limited effectiveness, and no alternative therapies
are currently available. As the present murine studies were near-
ing conclusion, a three year-old child with classic stigmata of
NF1 including a plexiform neurofibroma presented with progres-
sive life threatening airway compression. The tumor was origi-
nally diagnosed at age 6 months when a slow progressively
enlarging mass of the left floor of the mouth, tongue, neck, and
mastoid bone with encasement of the carotid artery and jugular
vein was biopsied and histologically confirmed to be a neurofi-
broma. The tumor was deemed unresectable given the vascular
involvement and she was observed clinically with sequential
magnetic resonance imaging (MRI) scans. Over the next 2 years,
the tumor progressed to cause upper airway compression (Fig-
ure 6) manifested by difficulty sleeping, poor appetite, and epi-
sodes of drooling. A sleep study showed frequent interruptions
of sleep but no oxygen desaturations to less than 91%. Based
on these findings, the attending physician placed the child on
350 mg/m2/dose of imatinib mesylate for a limited trial. The par-
ents provided consent for the use of imatinib mesylate following
discussion of the recent research results at our institutions, po-
tential risks and benefits of imatinib mesylate, and acknowledg-
ment that although imatinib mesylate was a widely used drug for
leukemias and solid tumors, including uses in infants, there was
no human data for imatinib mesylate in NF1 related tumors. MRI
scans before and after three months of treatment revealed a re-
markable approximately 70% reduction in tumor volume (Fig-
ures 6 and S7). Following treatment for six months with no ob-
served side effects (NCI CTC version 3 toxicity scale, http://
ctep.cancer.gov), MRI scans showed stabilization of her re-
sponse (Figure S7) without further reduction and the patient
came off treatment. Though reflecting the course of a single pa-
tient, this striking result is consistent with the preclinical studies
in the murine model.
DISCUSSION
Theories concerning the cellular andmolecular mechanisms that
underlie the development of idiopathic cancer have undergone
significant evolution in recent years. The original notions that
cell autonomous events convey a single cell to overcome its nor-
mal regulation leading to development of malignant disease, and
furthermore the identity of the cell type of tumor origin, are pres-
ently under concerted reinvestigation. It is increasingly clear that
while a series of genetic and epigenetic events in a single cell
commence the trajectory toward a malignant phenotype, most
forms of cancer include a cooption of a permissivemicroenviron-
ment that allows and even promotes the tumorigenic state (Ha-
nahan and Weinberg, 2000). Following this hypothesis, a resis-
tant environment would essentially preclude the possibility of
tumor formation. Among identified noncell autonomous contrib-
utors to a coopted permissive process of tumor formation areneoangiogenesis, participation of the local stroma, and inflam-
mation, among other cell types (Bhowmick et al., 2004; Cous-
sens and Werb, 2002). The understanding of the precise order
of paracrine interactions, the relative importance, and themolec-
ular basis of the nontumorigenic environment interaction,
remains in infancy.
In this context, the development of murine mouse models that
might permit dissection of cell autonomous and noncell autono-
mous contributions to tumor development has gained consider-
able ascendance. Mouse tumor models clearly require rigorous
scrutiny in that the significance of such experimental strategies
can only be appreciated in the context of a clear and verifiable
physiological relevance to the human status. Therefore, a cardi-
nal principle in mouse modeling of human cancer requires that
mutations of relevant molecular pathways be developed in the
same tissues as the human tumors. Further, the mouse tumors
should recapitulate the human phenotype in a credible series
of cellular and molecular outcomes.
Neurofibromatosis type 1 is a single gene disease that in the
vast majority of cases is manifested by germline mutation and
therefore complete somatic heterozygosity followed by rare
loss of heterozygosity in cell types that engender the stereotypic
manifestations of this disease. Invariably tumors develop in the
peripheral nervous system. Human tissue studies suggested
a critical role for Schwann cells but suffered from relying on
a posteriori information to infer a preceding event. A conditional
Nf1 knockout mouse model that permitted tissue-specific dele-
tion of Nf1 has shed light on this process. In the physiologically
relevant context of global heterozygosity, these studies revealed
the genetic bottleneck for plexiform neurofibroma formation to
lie in the loss of Nf1 heterozygosity in the embryonic Schwann
cell lineage (Zhu et al., 2002). The histopathological analysis of
these tumors was indistinguishable from native human tumors.
The Microenvironment and Plexiform Neurofibromas
The power of mouse genetics further revealed a critical role for
a microenvironment that could in distinct genetic configura-
tions, be either tumor permissive or tumor resistant. Two key
observations prompted the idea that mast cells were strong
candidates to be critical participants in plexiform neurofibroma
initiation (Zhu et al., 2002). First was the realization that Nf1 het-
erozygosity outside the Schwann cell lineage was required for
tumor formation. Next, was the observation that mast cell infil-
tration into peripheral nerves appeared in these mice months
prior to tumor appearance, but not in the non tumorigenic Nf1
wild-type (flox/flox) genotype. Mast cells have been observed
in human neurofibromas although in the absence of a mouse
model, examination of a functional role in tumor development
or maintenance could not be directly studied. The requirement
for Nf1 haploinsufficiency has been replicated with additional
Cre transgenes that target the neural crest Schwann cell lineage
including periostin-Cre, P0-Cre and tamoxifen inducible PLP-
Cre, thus further validating the need for Nf1 heterozygosity out-
side the Schwann cell lineage (our unpublished data). The orig-
inal and now additional confirmatory data using tissue-specific
Cre transgenes do not preclude that tumors might be achiev-
able in a wild-type environment under contrived experimental
conditions. Indeed, when we utilize neural crest-specific CreCell 135, 437–448, October 31, 2008 ª2008 Elsevier Inc. 443
Figure 5. Treatment of Krox20;Nf1flox/ Mice with Imatinib Mesylate
(A) Change inmean FDG-PET-positive tumors after a 12 week treatment with imatinib mesylate. The temporal sequence of scans in three individual mice, and the
experimental treatment groups are identified (panels1–6). A schematic identifying a high resolution region of interest and representative regions of interest prior
and subsequent to treatment with imatinib mesylate are shown (panels 7 and 8).
(B) Summary of changes in mean FDG-PET intensity after a 12 week treatment with imatinib mesylate or PBS. Data are presented as mean ± SEM.
(C) Dissection of the peripheral nerves. Mean volume of dorsal root ganglia from all sciatic nerves of Krox20;Nf1flox/ mice treated with vehicle versus imatinib
mesylate. The solid line indicates mean volume of each respective group. Each symbol indicates the volume of an individual nerve. *p < 0.001 comparing vehicle
to imatinib mesylate.444 Cell 135, 437–448, October 31, 2008 ª2008 Elsevier Inc.
Figure 6. Evaluation of Imatinib Mesylate Efficacy in an Index Patient with a Plexiform Neurofibroma
Coronal MRI scans (T1 weighted images with gadolinium contrast and fat saturation) of the head and oropharynx of an NF1 patient with a plexiform neurofibroma
before (panel 1) and 3 months following treatment with imatinib mesylate (panel 2). The region of the tumor in the respective images is indicated.drivers that have early, widespread, and robust expression,
thus driving Nf1 nullizygosity throughout neural crest-derived
cells, we observe hyperplasia of the peripheral nerves even in
flox/flox mice, although less so than in the flox/ condition (un-
published data). We believe these latter models depart from the
physiological situation in humans with NF1 wherein LOH is
a rare stochastic event. In human patients with NF1, a rare em-
bryonic LOH event renders a Schwann Nf1/ cell in isolation
and at relative disadvantage within its microenvironment to
mount tumor formation as compared to experimental supraphy-
siologic disruption in broad fields of Nf1/ Schwann cells. Our
mouse models indicate that an isolated Nf1/ pocket of
Schwann cells gains a significant selective advantage by an ev-
ident synergy with recruited heterozygous mast cells. We inter-
pret the hyperplasia in robust Cre embryonic mediated recom-
bination models to reflect a nonphysiologic widespread loss of
Nf1, not only in most Schwann cells but also in additional neural
crest lineages that may help to partially overcome the barriers of
isolated LOH.
Nf1 Heterozygous Mast Cells Require c-kit for Tumor
Formation and Maintenance
The finding that transplantation of WT bone marrow into tumor
prone Krox20;Nf1flox/ mice rescues tumorigenicity establishes
that the requirement for haploinsufficiency resides in bone mar-
row-derived cells but not other cell types found in these tumors.
Conversely, genetic disruption of c-kit signaling in the donor
bone marrow, resulting in failure of donor heterozygous mast
cells to infiltrate peripheral nerves and absence of tumors
strongly supports the hypothesis that this constitutes a causal in-
teraction.The c-kit receptor has a central role in mast cell development
and function (Huang et al., 1990). Schwann cells and fibroblasts,
two principal components of neurofibromas, secrete kit-ligand in
response tomany different stimuli (Hirota et al., 1993; Ryan et al.,
1994). Elevated kit-ligand mRNA transcripts have been reported
in neurofibroma tissue and it has been reported that NF1 patients
have elevated levels of kit ligand in serum (Mashour et al., 2004).
We therefore turned to imatinib mesylate, an FDA-approved
pharmacological agent that has inhibitory activity on several ty-
rosine kinases including c-kit in preclinical trials. In tissue culture
studies,we found that the ability of conditionedmedia fromNf1/
Schwann cells to hyper stimulate proliferation of cultured hetero-
zygous (Nf1+/) mast cells is essentially blocked by imatinib me-
sylate (data not shown; Yang et al., 2003). We were surprised by
the dramatic activity of this drug to reverse the neurofibroma pa-
thology in our mouse model accompanied by disappearance of
mast cells from the peripheral nerves. In addition to extending
our in vitro studies that demonstrated c-kit mediated interactions
between Nf1/ Schwann cells and heterozygous mast cells
(Yang et al., 2003), the in vivo studies identify a persisting
requirement for imatinib mesylate-susceptible cells for tumor
maintenance. Whether sustained treatment is required after
tumor regression awaits further investigation.
The role of inflammatory cells in tumor development is an active
area of research (Coussens et al., 1999, 2000; Coussens and
Werb, 2002). It is now evident that inflammatory cells are critical
to the early genesis of evolving neoplasms and it is implicated in
a wide range of murine tumorigenesis models, including breast,
ovarian (Kacinski, 1995), pancreatic (Bergers et al., 2000), and
skin models (Coussens et al., 1999). The presence of mast cells
in neurofibromas is an old and accepted observation that has led(D) Histological analysis of theKrox20;Nf1flox/mice treated with imatinib mesylate or vehicle. Representative sections were shown following H&E staining, Alcian
blue staining, and Masson’s trichrome staining. The experimental therapy, the stains utilized to prepare the specimens, and the magnification are indicated. Red
arrows identify mast cells found on the respective sections.
(E) Imatinib mesylate reduces mast cell numbers in plexiform neurofibromas. Summary data of mast cells per 1003 field of Krox20;Nf1flox/ mice treated with
imatinib mesylate or vehicle. Data represent mean ± SEM of mast cells/ high power field from 10 fields of 12 tumors/DRG; an asterisk indicates p < 0.01 statistical
difference between groups.
(F and G) Imatinib mesylate induces apoptosis (F) and reduces proliferation (G) in plexiform neurofibromas. Summary data (mean ± SEM) of (F) apoptotic and (G)
BrdU+ cells / high power field imatinib mesylate versus placebo; an asterisk indicates p < 0.01 statistical difference between groups.
Cell 135, 437–448, October 31, 2008 ª2008 Elsevier Inc. 445
to speculation about a potential active role in tumor development
or maintenance. Mast cells have also been implicated in other
skin malignancies in both human and murine systems (Coussens
et al., 1999; Galli et al., 1993; Hirota et al., 1993; Ryan et al., 1994).
Mast cells release mediators of inflammation including hista-
mine, serotonin, proteoglycans, and leukotrienes subsequent
to activation of the high affinity IgE receptor (Fc3RI) and the
c-kit receptor (Galli et al., 1993; Boesiger et al., 1998). Further,
mast cells release VEGF (Boesiger et al., 1998), an angiogenic
factor that is also a potent proliferative, survival, and chemotac-
tic factor for Schwann cells (Sondell et al., 1999). VEGF has also
been linked to an angiogenic switch in tumor formation (Bergers
et al., 2000). Finally, mast cells also release PDGF-BB, a growth
factor that promotes pericyte and fibroblast proliferation; and
TGF-b, a growth factor that promotes fibroblast proliferation
and collagen synthesis.
Imatinib Mesylate and the Tumor Microenvironment
In the context of neurofibromas, how do mast cells cooperate
with Schwann cells to elicit tumor formation?We show that other
cell types in the tumor needn’t have NF1mutations. However, we
cannot at this time assert whether the infiltrating Nf1 heterozy-
gous mast cell primarily acts reciprocally on the Nf1-deficient
Schwann cells to promote tumor formation or alternatively
whether indirect interaction with local stroma and additional
cell types also present in these tumors are requisite intermediar-
ies for tumor induction. Studies are underway to gain a better
understanding of additional paracrine interactions within neuro-
fibromas and how they may impinge on tumor formation and
maintenance. In addition to the above genetic results, our previ-
ous in vitro studies demonstrated that imatinib mesylate inhibits
multiple Nf1+/ pericyte, and fibroblast tumor promoting func-
tions (Li et al., 2006; Munchhof et al., 2006; Yang et al., 2006).
Again, despite the absence of requirement for heterozygosity
in these additional tumor cells, we cannot rule out that the activity
of imatinib mesylate in regressing tumors may extend beyond its
inhibitory activity on mast cells. Imatinib mesylate could in
principle fortuitously inhibit additional potentially critical tumor
promoting activities of other cell types. For instance in addition
to inhibiting c-kit in mast cells, imatinib mesylate may decrease
angiogenesis by blocking PDGF receptor and/or reduce
fibrosis/collagen production by blocking c-abl. Additional inves-
tigation will be required to resolve these critical and fascinating
scenarios.
A critically ill three year-old child with a plexiform neurofibroma
compressing her airway was administered imatinib mesylate
therapy in a compassionate use protocol and responded
dramatically to this therapy. This encouraging and coincident
result together with results obtained from our mouse model
has prompted a Phase 2 clinical trial to determine the efficacy
of this treatment for plexiform neurofibromas. One cautionary
note concerns the limitation that ourmousemodel has a relatively
short lifespan. On the basis of one-yearmouse tumor studies, we
cannot predict with certainty how long-lived tumors might be ex-
pected to respond to imatinib mesylate. It is also conceivable
that long lived tumor cells in NF1 patients may accrue additional
properties over time that render them independent of certain
early paracrine events such as the mast/Schwann cell nexus.446 Cell 135, 437–448, October 31, 2008 ª2008 Elsevier Inc.Conclusions
The present studies provide an example of a physiologically
relevant mouse model of a human cancer that has provided
concrete insights into complex interactions between the tumor
cell of origin and the microenvironment. On the basis of these
studies, we have developed a potential therapeutic approach
for a heretofore untreatable tumor by targeting themicroenviron-
ment rather than the tumorigenic cell. Should the activity of
imatinib mesylate prove to be validated in clinical trials, unlike
the situation with this drug in treatment of chronic myelogenous
leukemia, we would not anticipate the eventual development of
drug resistance. In CML, the action of imatinib mesylate is di-
rectly on the leukemic cell and aimed at a mutated constitutively
active tyrosine kinase oncoprotein (Bcr-abl). The Bcr-abl onco-
gene can develop drug resistance through acquisition of second
site mutations (Sawyers, 2005). In contrast, we believe that the
principal if not exclusive activity of imatinib mesylate on neurofi-
bromas is on non tumor cells acting on wild-type proteins for
which there is presumably no pressure for selection for drug
resistance. Currently, we have identified compounds that
in vitro have as much as tenfold higher inhibitory activity on
Nf1 heterozygous mast cells than does imatinib mesylate (un-
published data). Preclinical tests will help determine whether
these compounds will exhibit increased potential for therapeutic
avenues in NF1. It is interesting to note that extremely rare
patients have been reported that have both neurofibromatosis
type 1 and piebaldism, a rare neural crest disease that affects
pigmentation and the enteric nervous system. Although not di-
rectly evaluated, based on independent studies on themolecular
basis of piebaldism, the authors of these studies inferred, that
piebaldism presumably resulted from hypomorphic mutations
of the c-kit receptor. Remarkably, these patients were reported
to lack neurofibromas (Chang et al., 1993; Tay, 1998). In retro-
spect, it is highly likely that these NF1/piebald patients were de-
ficient in mast cells thus providing a human confirmation of the
importance of c-kit and mast cells in neurofibroma formation.
In closing we suggest that the genetic and cellular malleability
of our neurofibroma mouse model may reveal important details
about microenvironment participation and paracrine cell interac-
tions in tumor formation that will have general relevance for
human cancer outside the context of neurofibromatosis type 1.
EXPERIMENTAL PROCEDURES
Animals and Reagents
The Krox20;Nf1flox/flox mice and Krox20;Nf1flox/ mice have been previously
described (Zhu et al., 2002). The C57BL/6-TgN(ACTbEGFP)1Osb mice
were obtained from Jackson Laboratory, Bar Harbor, ME. Chemicals were
purchased from Sigma (St. Louis, MO) unless otherwise stated.
Bone Marrow Transplantation of Hematopoietic Cells
Twomillion syngeneic WT or Nf1+/ bone marrow cells fromWTGFP orNf1+/
GFP mice per recipient were transplanted into young adult Krox20;Nf1flox/flox
mice or Krox20;Nf1flox/ mice following 1100 rads of ionizing radiation.
PET Imaging Analysis
Fluorodeoxyglucose ([18F] FDG) PET and X-ray CT imaging was employed to
identify neurofibromas. CT images were used to place a standardized volume
of interest (VOI) template over regions lateral to the spinal cord for quantifica-
tion of FDG uptake. Registered and overlaid CT image data was used to
identify specific vertebrae landmarks from Lumbar (L1) to the Sacrum (S1). The
user then picked points along the spinal cord to determine the path of the spi-
nal cord between L1 and S1. Three circular regions-of-interest (ROI) are then
placed at interpolated points along the spinal cord to capture the spinal cord
and the dorsal root ganglion regions. The circular ROI’s then were combined
to create VOI’s for the spinal cord, left dorsal root ganglion, and right dorsal
root ganglion. FDG images were acquired at 45 min postinjection of 0.5–1.0
mCi of FDG via tail vein injection. All animals were administered FDG while
awake and given isoflurane anesthesia at 40 min postinjection to immobilize
the animal for imaging.
Dissection of Dorsal Root Ganglia
Immediately following postmortem, mice were perfused and fixed in 4%
paraformaldehyde. The dorsal root ganglia and peripheral nerves were then
dissected out under a dissection microscope.
Measurement of Tumor Size
The volume of tumors was determined by the established approximate volume
for a spheroid 0.52 3 (width)2 3 length.
Phenotypic Evaluation of the Donor Cells in Dorsal Root Ganglia
Ganglia were minced, digested by collagenase V, and the single cell suspen-
sion was admixed with anti CD117, CD31, or Col1A and Fc3RI antibodies.
Populations were separated using a fluorescence-activated cell sorter (Becton
Dickson, San Jose, CA).
Genotypic Analysis of Donor Bone Marrow
DNA was isolated as described (Clapp et al., 1995), digested with PstI to
elucidate the Nf1 knockout and Nf1flox/flox fragments and separated by gel
electrophoresis. Following transfer to a nitrocellulose filter, fragments were
hybridized with an Eag I/ Sph I, 32P dATP labeled neo fragment, washed,
and exposed to film as described (Clapp et al., 1995).
Histological Analysis
To examine the morphology of the tumors in detail, paraffin sections were
stained with hematoxylin and eosin (H&E), masson trichrome alcian blue as
described (Zhu et al., 2002).
In Vivo Evaluation of Proliferation and Survival in Tumors
Cell proliferation in tumors was evaluated by utilizing a BrdU in situ detection
kit (BD PharMingen, San Jose, CA). Krox20;Nf1flox/ mice previously treated
for 12 weeks with imatinib or vehicle, received 50 mg BrdU per Kg of body
weight), 48, 24, 6, 4, and 2 hr via peritoneal injection before intracardiac perfu-
sion. DRGs were processed for paraffin-embedding immunohistochemical
staining and BrdU positive cells were counted under a phase contrast micro-
scope. Apoptosis of tissues was evaluated using TUNEL staining as described
(Hiatt et al., 2004).
Transmission Electron Microscopy
Following perfusion fixation, tissues were dehydrated in a graded series of
ethanol and acetone and embedded in Epon-Araldite (Electron Microscopy
Sciences, Hatfield, PA). Ultrathin sections (silver to gold) were stained with
uranyl acetate and lead citrate and examined with a FEI Tecnai G2 electron
microscope (Philips, Eindhoven, Netherlands).
Statistical Methods
Analysis of survival outcomes was performed using the Kaplan-Meier method.
Comparison of themean size of tumors, differences in cellularity and apoptosis
in the experimental groups was performed using Student’s t test or analysis of
variance.
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